Targets › MSTN
3 programs from 3 companies in 8 trials: 6 Phase 2, 1 Phase 3, 1 Phase 1; Neurology, Metabolic and endocrine; next expected readout Nov 2026.
Acts specifically as a negative regulator of skeletal muscle growth. (UniProt, O14793)
Open in Phaseline: the race on MSTN, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Scholar Rock | Apitegromab Growth/differentiation factor 8 inhibitor | MSTN | Phase 3 | Spinal Muscular Atrophy; Facioscapulohumeral Muscular Dystrophy | Jun 2028 |
| Roche | RO7204239 Anti-myostatin antibody | MSTN | Phase 2 | Facioscapulohumeral Muscular Dystrophy (FSHD); Spinal Muscular Atrophy (SMA); Obesity; Type 2 Diabetes Mellitus | Nov 2026 |
| Regeneron Pharmaceuticals | Trevogrumab GDF8 (myostatin) inhibitor | MSTN | Phase 2 | Obesity | – |
Spinal Muscular Atrophy (2) Obesity (2) Facioscapulohumeral Muscular Dystrophy (1) Facioscapulohumeral Muscular Dystrophy (FSHD) (1) Spinal Muscular Atrophy (SMA) (1) Type 2 Diabetes Mellitus (1)
mixed (2), small molecule (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.